IonDX™ Starts An Early Access Program
Monterey, CA, April 1,2021: IonDX Inc.™ Inc., a lifesciences instrumentation company, has initiated an Early Access Program in support of launching their first product, the IMGenius™ system, at ASMS 2021. IonDX is focused on developing biotherapeutic analytical solutions to support accelerated drug development.
“The Early Access Program is a structured product introduction aimed at select biopharma industry customers prior to the official launch. This pre-commercial engagement process will ensure the long-term success of IMGenius”, said Ms. Ananya Dubey Kelsoe, Executive Director of Business and Corporate Development at IonDX.
IonDX’s technology is atmospheric pressure ion mobility spectrometry that analyzes biologically relevant native conformations of proteins, protein complexes and nucleic acid modalities. The company is currently involved in several industry-wide collaborations (confidentiality agreements prevent disclosure). IonDX is planning to launch its first bench-top spectrometer in Q3 of this year and is currently engaging with key technology adopters.
For more information on the Early Access Program or to learn more about the IMGenius system, please contact:
Senior Commercialization Specialist, IonDX
GlycoSeLect and IonDx Inc., Collaborating on High-throughput Glycoprotein Analyses
Monterey, CA, USA and Dublin Ireland ‐ November 16, 2020 – GlycoSeLect Ltd and IonDx Inc. are actively engaged in a research collaboration to evaluate the use of Recombinant Prokaryotic Lectins (RPLs) and IonDx’s Ion Mobility Spectrometry technology as a new way to screen glycoproteins rapidly.
“GlycoSeLect’s glycan specific lectins provide a high degree of specificity that will improve detection, monitoring and profiling of glycosylation within a wide range of biotherapeutics. Hence, we are excited to join GlycoSeLect and apply our ion mobility technology to all phases of biotherapeutic production and help manufacturers streamline this analytical bottleneck”, said Ms. Ananya Dubey Kelsoe, Executive Director of Business and Corporate Development at IonDx Inc.
Robert Dunne, GlycoSeLect CEO commented that “The GlycoSeLect team is pleased to work with our friends in IonDx. Our RPL technology has been shown to be highly specific in detecting glycan structures which is vital for the analysis of biotherapeutic products. The IonDx team has developed impressive ion mobility technology and applications potential for fast routine batch to batch screening or clone selection. The combination of our technologies bodes well for developing a more efficient workflow for biotherapeutic analytics”.
About GlycoSelect Ltd
GlycoSeLect Ltd develops innovative technologies for the analysis, characterisation and purification of biopharmaceuticals. These next-generation products are highly specific for glycan structures improving product development and improving the cost-efficiency of their manufacturing. GlycoSeLect specialises in the development of proteins based on recombinant prokaryotic lectins RPLs. Our RPL products advance efficient detection, analysis and selective isolation of glycosylated pharmaceutical products. GlycoSeLect’s family of RPLs products are associated with market-leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness in process development.
About IonDX Inc.
IonDx Inc. is an early stage Life Sciences instrumentation company that is focused on developing biotherapeutic analytical solutions to support accelerated drug development. The company is planning to launch its first spectrometer in Q3’ 2021 and is currently engaging with interested technology adopters. IonDx’s core technology is atmospheric pressure ion mobility spectrometry that quantifies the biologically relevant conformations (native structures) of proteins and protein complexes.
Please contact Robert Dunne at firstname.lastname@example.org or +353 87 7902652.
Please visit www.iondx.com and send questions at email@example.com
IonDx Receives another National Science Foundation Award
August 18, 2020: National Science Foundation (NSF) awarded IonDx Inc., a Monterey, CA-based lifesciences instrumentation company the Technology Enhancement for Commercialization Partnerships (TECP) supplemental fund to their existing SBIR Phase-II grant on “Ion Mobility Spectrometer for Macromolecular Analysis”. This additional award will help IonDx with their commercialization and business development efforts.
“Our ion mobility technology is continually finding new application areas and this funding will help us move into gene therapy and biotherapeutics process control,” said Dr. Henry Benner, IonDx’s CEO and Founder
“We are quite excited with NSF’s continuing support of IonDx. This TECP fund will enable us to advance our B2C and B2B engagements that are important for the long-term commercial success of our technology” said Ananya Dubey Kelsoe, Executive Director of Business and Corporate Development at IonDx.
Link to the SBIR Phase-II Award: https://nsf.gov/awardsearch/showAward?AWD_ID=1926636